55557-52-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloropyrazine-2-carbonitrile is used as a reactant for the synthesis of tuberculostatic pyrazine derivatives. These derivatives are compounds that have the potential to inhibit the growth of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. The application reason is that 3-Chloropyrazine-2-carbonitrile serves as a key building block in the chemical synthesis of these therapeutic agents, contributing to the development of new treatments for tuberculosis.

InChI:InChI=1/C5H2ClN3/c6-5-4(3-7)8-1-2-9-5/h1-2H

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 6863-76-9 3-chloropyrazine 1-oxide 
• 768-36-5 2-pyrazinecarboxamide-4-oxide 
• 25594-31-4 3-pyrazinecarbonitrile N-oxide 
• 19847-12-2 2-pyrazine carbonitrile 
• 2423-65-6 Pyrazin-N-Oxid(PyzNO) 
• 98-96-4 pyrazinamide 
• 55321-99-8 3-hydroxy-2-pyrazinecarboxamide 
• 55321-99-8 3-oxo-3,4-dihydropyrazine-2-carboxamide 
• 1378802-34-6 4-(3-chloropyrazin-2-yl)-2-methylbut-3-yn-2-ol 

Downstream Products

• 56881-21-1 ethyl 7-aminothieno[2,3-b]-pyrazine-6-carboxylate 
• 25911-65-3 2-amino-3-pyrazinonitrile 
• 75018-05-2 3-methoxypyrazinecarbonitrile 
• 175203-31-3 3-Chloro-N-hydroxy-pyrazine-2-carboxamidine 
• 81411-64-5 3-aminopyrazolo<3,4-b>pyrazine 
• 500731-37-3 1-methyl-1H-pyrazolo[3,4-b]pyrazin-3-ylamine 
• 880874-31-7 4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-carbonitrile 
• 880874-34-0 4-benzyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-carbonitrile 
• 944240-44-2 C₁₈H₁₈ClN₅O₂ 
• 67130-86-3 3-morpholin-4-yl-pyrazine-2-carbonitrile 
• 504436-32-2 N-[5(S)-3-[4-[(1α,5α,6α)-6-(3-cyanopyrazin-2-yl)amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide 
• 1015081-23-8 3-[(4-methoxybenzyl)amino]pyrazine-2-carbonitrile 
• 664308-21-8 4-(4-cyanophenyl)-3,4,5,6-tetrahydro-2H-[1,2']-bipyrazinyl-3'-carbonitrile 
• 1280212-29-4 5-cyano-6-(cyclohexylamino)pyrazine-2-carboxamide 

Relevant academic research and scientific papers

Synthesis method of 7-bromothieno [2, 3-B] pyrazine

The invention provides a preparation method of 7-bromothieno [2, 3-b] [1, 2, 4] thiadiazole. The invention discloses a synthetic method of 2, 3-B] pyrazine. Relating to the organic synthesis field, the preparation method comprises the following steps: reacting 2, 3-dichloropyrazine with 2-methyl-3-butyne-2-ol, cuprous iodide and triethylamine under the catalytic action of tetrakis (triphenylphosphine) palladium to generate 2-methyl-4-(3-chloropyrazine)-3-butyne-2-ol; 2-methyl-4-(3-chloropyrazine)-3-butyne-2-ol reacts with alkali to obtain 2-chloro-3-ethynylpyrazine, 2-chloro-3-ethynylpyrazinereacts with sodium sulfide nonahydrate to generate thieno [2, 3-B] pyrazine, and thieno [2, 3-B] pyrazine further reacts with N-bromosuccinimide to generate 7-bromothieno [2, 3-. The synthesis methodprovided by the invention has the advantages of easily available raw materials, mild reaction conditions, high selectivity, good operability of post-treatment, high yield and easiness in large-scale production.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a cyclobutane substituent group-containing pyrazine compound and application thereof as a drug, and particularly relates to application of the cyclobutane substituent group-containing pyrazine compound in preparing the drug for preventing and treating various influenza viruses. Especially, the invention relates to a compound as shown in a general formula (I) or a stereomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and various variables are defined in the specification. The invention also relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug, and particularly relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug for preventing and treating the influenza viruses.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a cyclobutane substituent containing pyrazine compound, a use of the cyclobutane substituent-containing pyrazine compound as a medicament, and particularly application to the preparation of a medicament for preventing and treating various influenza viruses. Particularly, the invention relates to a compound as shown in general formula (I), or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound, wherein each variable is defined in the description. The invention also relates to the use of the compound as shown in general formula (I) or the stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as a medicament, particularly the use as a medicament for preventing and treating influenza viruses.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a pyrazine compound containing a diethylene substituent and application thereof as a medicine, particularly application thereof to preparation of medicines for preventing and treating various influenza viruses. Particularly, the invention relates a compound of which the general formula I is shown in the specification, or a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and all variables are defined in the specification. The invention also relates to application of the compound of which the general formula I is shown in the specification, or the stereoisomer, the geometrical isomer, the tautomer, the nitrogen oxide, the hydrate, the solvate, the metabolite, the pharmaceutically acceptable salt or the prodrug thereof as medicines, particularly application of the compound as a medicine for preventing and treating influenza viruses.

Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution

A series of 19 new compounds related to pyrazinamide were synthesized, characterized with analytical data and screened for in vitro whole cell antimycobacterial activity against Mycobacterium tuberculosis H37Rv, Mycobacterium kansasii and two types of Mycobacterium avium. The series consisted of 3-(benzylamino)-5-cyanopyrazine-2-carboxamides and 3-(benzylamino)pyrazine-2,5-dicarbonitriles with various substituents on the phenyl ring. RP-HPLC method was used to determine the lipophilicity of the prepared compounds. Nine compounds exerted similar or better activity against Mycobacterium tuberculosis compared to pyrazinamide (MIC = 6.25-12.5 μg/mL). 3-(Benzylamino)pyrazine-2,5-dicarbonitrile inhibited all of the tested mycobacterial strains with MIC within the range 12.5-25 μg/mL. Although not the most active, 4-NH2 substituted compounds possessed the lowest in vitro cytotoxicity (hepatotoxicity), leading to selectivity index SI = 5.5 and SI >21.

Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles

A series of 14 new compounds related to pyrazinamide were synthesized, characterized with analytical data and screened for in vitro antimycobacterial activity against Mycobacterium tuberculosis, Mycobacterium kansasii and two types of Mycobacterium avium. The series comprised of N-substituted 3-aminopyrazine- 2,5-dicarbonitriles derived from 3-chloropyrazine-2,5- dicarbonitrile by nucleophilic substitution of chlorine by various non-aromatic amines (alkylamines, cycloalkylamines and heterocyclic amines). Noteworthy antimycobacterial activity against M. tuberculosis was found among the alkylamino derivatives, for example, 3-(heptylamino)pyrazine-2,5-dicarbonitrile inhibited M. tuberculosis at MIC = 51 lmol/L. 3-(Hexylamino)pyrazine-2,5- dicarbonitrile inhibited M. kansasii at MIC = 218 lmol/L. Basic structure-activity relationships are discussed. A comparison between calculated and experimentally determined lipophilicity parameters within the series is included.

Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d] pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors

A useful and rapid access to libraries of N-arylbenzo[b]thieno[3,2-d] pyrimidin-4-amines and their pyrido and pyrazino analogues was designed and optimized for the first time via microwave-accelerated condensation and Dimroth rearrangement of the starting anilines with N′-(2-cyanoaryl)-N,N- dimethylformimidamides obtained by reaction of thiophene precursors with dimethylformamide dimethylacetal. The inhibitory potency of the final products against five protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, DYRK1A and CLK1) was estimated. N-arylpyrido[3′,2′:4,5]thieno[3,2-d] pyrimidin-4-amine series of compounds (4a-j) turned out to be particularly promising for the development of new pharmacological inhibitors of CK1 and CLK1 kinases.

Derivatives of pyrazinecarboxylic acid: 1H, 13C and 15N NMR spectroscopic investigations

NMR spectroscopic studies are undertaken with derivatives of 2-pyrazinecarboxylic acid. Complete and unambiguous assignment of chemical shifts (1H, 13C, 15N) and coupling constants (1H,1H; 13C,1H; 15N,1H) is achieved by combined application of various 1D and 2D NMR spectroscopic techniques. Unequivocal mapping of13C,1H spin coupling constants is accomplished by 2D (S,J) long-range INEPT spectra with selective excitation. Phenomena such as the tautomerism of 3-hydroxy-2-pyrazinecarboxylic acid are discussed.

Synthesis, antimycobacterial and antifungal evaluation of 3-arylaminopyrazine-2,5-dicarbonitriles

This paper describes preparation and biological evaluation of pyrazinamide analogues. Pyrazinamide with its simple structure gives a good opportunity for further modification regarding an increase of its antimycobacterial activity. We prepared a series of compounds derived from pyrazine-2,5-dicarbonitrile with arylamino substitution in position 3. All compounds were assayed in vitro against major Mycobacterium and various Fungi species. The best activity was found in 3-{[3-(trifluoromethyl)phenyl]amino}pyrazine-2,5-dicarbonitrile 11 with the value of 6.25 μmol-1 against M. tuberculosis H37Rv and moderate activity against minor Mycobacterium pathogens.

FUSED FURAN COMPOUND

The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and , R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.